Drug intelligence / Profile preview

AB100

Development stage: Preclinical
Lead developer: Aromics
Modality: Small Molecules

Overview

AB100 is a preclinical-stage small molecule antiviral candidate being developed by Aromics for the treatment of Herpes Simplex Virus (HSV) infections. The compound was identified through Aromics' proprietary drug discovery platform, which focuses on identifying small molecules that modulate gene expression by targeting RNA or RNA-protein interactions. AB100 has demonstrated in vitro proof-of-concept (PoC) by inhibiting viral replication. It is intended to address the need for new therapeutic options for HSV-1 and HSV-2, particularly in cases of resistance to standard nucleoside analogs like acyclovir.

Targets

HSV-1 (Herpes simplex virus type 1)

Beyond the preview

Go deeper on AB100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AB100.

Explore the full profile